跳至主要内容
临床试验/CTRI/2024/09/074104
CTRI/2024/09/074104已完成3 期

A single arm open label interventional study to evaluate the efficacy and tolerability of Amrutanjan pain balm extra power for pain relief in patients with primary type of headache disorders

Amrutanjan Health Care Limited, Tamil Nadu, India1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2025年8月5日最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
24
试验地点
1
主要终点
To assess the onset of pain reduction after treatment from

研究概览

简要总结

24 participants with primary type of headache disorders will be enrolled in this study in a single arm.Test Arm – Participants (24) with primary headache disorders will use Amrutanjan Pain balm extra Power twice or thrice daily topically for one day

Subjects will be asked to visit clinical facility/institution for their follow up visits on day 2. The subjects who fulfilled the inclusion and exclusion criteria will be enrolled in the study.

24 participants will be randomized into a single group.

Test Arm – Participants (24) with primary headache disorders will use Amrutanjan Pain balm extra Power twice or thrice daily topically for one day

Subjects will be asked to visit clinical facility/institution for their follow up visits on day 2.

The primary outcome measures to study the efficacy are as follows:

To assess the onset of pain reduction after treatment from 30 seconds up to 15 minutes continuously

and then on hourly basis for 24 hours. (using visual analog scale)

To assess the duration of action/ pain relief (i.e. need for second application) of the test product for

pain relief. (time frame : 0-24 hours)

Visual analog scale (VAS) questionnaires will be filled in by the patients and scores given, ranging

from 0 to 10 (based on the severity of pain).

For statistical analysis, ordinal conversion of pain levels will be assigned as 0–no pain up to 10-

severe pain.

To monitor other complications like nausea, vomiting, photophobia, and phonophobia.

To monitor for any adverse events during the study period.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 80.00 Year(s)(—)
性别
All

入选标准

  • Patients of either sex aged above 18 years.
  • Patients who can understand written and/or verbal instructions and are ready to comply with all study requirements with a willingness to participate and give written informed consent voluntarily.
  • Patients who had been diagnosed with primary type of headache disorders like migraine, tension type headache and other primary head ache disorders.

排除标准

  • Women of childbearing potential who are either unwilling or unable to use an acceptable method of birth control such as oral contraceptives, other hormonal contraceptives implants or injectable products, vaginal products, skin patches, or IUDs, barrier methods] to avoid pregnancy during the study period.
  • Secondary type of headache disorders.
  • Known allergy to compounds of investigational product.
  • Subjects who had a diagnosis of basilar or hemiplegic migraine.
  • Patients suffering from medical or psychiatric conditions that would increase the risk of adverse events or interfere with study assessments.
  • Participation in an investigational drug trial in the 30 days prior to the screening visit.
  • Immuno-compromised (history) individuals like known HIV positive patients or patients who are on treatment with steroids or immunomodulators.
  • Patients of vulnerable group (children, lactating mother, elderly greater than 80 years, handicapped, seriously ill, mentally challenged).
  • History of drug or alcohol abuse during the last 6 months.

结局指标

主要结局

To assess the onset of pain reduction after treatment from

时间窗: 30 seconds up to 15 minutes continuously and then on hourly | basis for 24 hours

30 seconds up to 15 minutes continuously and then on hourly

时间窗: 30 seconds up to 15 minutes continuously and then on hourly | basis for 24 hours

basis for 24 hours using visual analog scale

时间窗: 30 seconds up to 15 minutes continuously and then on hourly | basis for 24 hours

To assess the duration of action ie need for second

时间窗: 30 seconds up to 15 minutes continuously and then on hourly | basis for 24 hours

application of the test product for pain relief time frame

时间窗: 30 seconds up to 15 minutes continuously and then on hourly | basis for 24 hours

0-24 hours

时间窗: 30 seconds up to 15 minutes continuously and then on hourly | basis for 24 hours

the severity of pain

时间窗: 30 seconds up to 15 minutes continuously and then on hourly | basis for 24 hours

For statistical analysis ordinal conversion of pain levels will

时间窗: 30 seconds up to 15 minutes continuously and then on hourly | basis for 24 hours

be assigned as 0 no pain up to 10-severe pain.

时间窗: 30 seconds up to 15 minutes continuously and then on hourly | basis for 24 hours

次要结局

  • To monitor other complications like nausea, vomiting,(photophobia, and phonophobia.)

研究者

发起方
Amrutanjan Health Care Limited, Tamil Nadu, India
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Anand Babu MBBS

Shree Lakshmi Clinic

研究点 (1)

Loading locations...

相似试验